In 2010, royalty and license income totaled EUR 339.4 million (2009: EUR 344.9 million) and mainly included royalty and license income from the products Avonex® (Biogen Idec), Humira® (Abbott), Enbrel® (Amgen), Puregon® (Merck & Co.) and vilazodone (Clinical Data), as well as income from the active pharmaceutical ingredients bisoprolol and metformin.
In 2010, commission income totaled EUR 22.3 million (2009: EUR 24.4 million). This primarily consisted of cooperation and distribution agreements, such as for Ikorel® (Sanofi-Aventis), Euthyrox® (Bracco) and Allergan products. The breakdown of royalty, license and commission income by business sector and division is presented in the Segment Reporting.
back
